[What physicians think and know about antithrombotic therapy in atrial fibrillation]
| Autor: | Komkov Ds, O.G. Kompaniets, Nedbaĭkin Am, Linchak Rm, Iusova Ia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty Quality Assurance Health Care Attitude of Health Personnel media_common.quotation_subject Risk Assessment Russia Fibrinolytic Agents Physicians Surveys and Questionnaires Antithrombotic Atrial Fibrillation medicine Humans cardiovascular diseases Stroke media_common Aspirin business.industry Warfarin Atrial fibrillation Systemic embolism Limiting medicine.disease Emergency medicine Clinical Competence Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | CURANS Europe PubMed Central ResearcherID |
| ISSN: | 0022-9040 |
| Popis: | We conducted an anonymous survey among 382 physicians (58% internists, 42% cardiologists) in order to obtain information on their opinion on various aspects of antithrombotic therapy in atrial fibrillation. The survey revealed low level of awareness about algorithms of stratification of risks of stroke, systemic embolism, and bleeding. Reported rates of clinical use of recommended antithrombotic agents were: warfarin--30, aspirin monotherapy--19, dabigatran--10, rivaroxaban--8, and combination of aspirin and clopidogrel--8%. Rate of use of drugs without sufficient evidence base in AF was 25%. When asked to designate antithrombotic drug of choice 85% of physicians indicated warfarin and 12%--novel anticoagulants (NOAC). The following factors were considered as limiting wide application of NOAC: high cost (59%), lack of data on these drugs (14%), and impossibility to control safety of their administration (9%). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|